Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ITCH Clear all
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

NCT05133830
View directory record Official record
Conditions
Pruritus
Interventions
Obeticholic acid, Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional Results available

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

NCT04718961
View directory record Official record
Conditions
Intrahepatic Cholestasis of Pregnancy
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury

NCT01795079
View directory record Official record
Conditions
Burn Injury, Chronic Pain, Pruritus, Itching
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Management of Pruritus With Xyzal in Atopic Dermatitis

NCT00884325
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
Levocetirizine dihydrochloride (Xyzal), placebo
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Not applicable Interventional

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

NCT05226143
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Gel Cream
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

NCT05061693
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Fountain Valley, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Ketoconazole Cream 2%

NCT04203342
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.), Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA), Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Drug
Lead sponsor
Douglas Pharmaceuticals America Ltd
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Brandon, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

NCT04256759
View directory record Official record
Conditions
Pruritus
Interventions
Dupilumab 300Mg Solution for Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 9:39 AM EDT
Recruiting Not applicable Interventional

Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch

NCT06751056
View directory record Official record
Conditions
Pruritus
Interventions
Cervical Traction Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 4 Interventional Results available

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

NCT01825655
View directory record Official record
Conditions
Pruritus
Interventions
Cetirizine, Placebo or sugar pill
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

NCT01636687
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593
View directory record Official record
Conditions
Tinea Pedis
Interventions
TA103, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

NCT05393076
View directory record Official record
Conditions
Pruritus
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

NCT02057718
View directory record Official record
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions
LUM001 (Maralixibat)
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

NCT00838708
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
SRD174 Cream, vehicle cream
Drug · Other
Lead sponsor
Serentis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2009 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)

NCT03422653
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845 0.5 mcg/kg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
57
States / cities
Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

NCT01905631
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Aurstat Anti-Itch Hydrogel (Aurstat)
Drug
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Jun 10, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jun 10, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional

SAMe to Treat Biliary Cirrhosis Symptoms

NCT00125281
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
S-adenosyl-methionine (SAMe) capsules
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:39 AM EDT